source
- Argenx’s FB102 meets primary endpoint in phase 2 celiac trial, paving way for pivotal studyArgenx reported that its experimental antibody FB102 achieved a statistically significant improvement in villus height‑to‑crypt depth (Vh:Cd) compared with placebo in a phase 2 study of adults with…
- New PDUFA agreement earmarks funds to rehire FDA reviewers after recent layoffsTrade groups report that the latest PDUFA reauthorization includes a specific funding pool for the FDA. The money is intended to replace reviewers who were let go after recent HHS staffing reducti…